Tirzepatide activates GLP-1 and GIP receptors, while Retatrutide activates GLP-1, GIP, and glucagon receptors and is therefore described as a triple hormone receptor agonist or, informally, a GLP-3 medication
The outer carton includes specific elements: a unique lot number, expiration date printed (not handwritten), and tamper-evident packaging
For people on GLP-1 medications who are working on building healthier eating patterns, alcohol can undermine these efforts by triggering old patterns of overeating or making impulsive food decisions
[1] These combined actions lead to improved glycemic control and significant weight reduction, with clinical trials in adults without diabetes demonstrating average weight loss of 15-22% of body weight over 72 weeks in the SURMOUNT-1 trial
Industry leaders Novo Nordisk and Eli Lilly have a tremendous head start in production, distribution and marketing, and it shows
There are some rare but serious risks, like inflammation of the pancreas or thyroid concerns